Whalesbook
Dekho, company ko USFDA se approval mil gaya hai is generic dapagliflozin aur metformin hydrochloride extended-release tablets ke liye. Toh ab yeh US ke jo bade anti-diabetic market mein ghus gaye hain. Waise yeh market $33.8 billion se bhi bada hai, aur sirf generic dapagliflozin ka segment $10 billion cross karta hai. Lekin asli picture yeh hai ki yahan competition itna hai ki entry mushkil ho jayegi.
Jabardast competition hai bhai! Ek taraf toh AstraZeneca ka original Xigduo XR hai, jiske patents 2028 tak ya shayad 2031 tak chalenge. Aur doosri taraf, Aurobindo Pharma jaise companies bhi aa gayi hain jinko USFDA ne approval de diya hai aur woh bhi launch karne wale hain. Matlab seedha price war shuru ho jayegi jisse sabke profit margins kam ho sakte hain.
Ab company ke numbers dekhte hain. Lupin ki market cap hai lagbhag ₹1.05 lakh crore, aur P/E ratio around 22.8x hai, jo pharma sector ke hisaab se normal hai. Share price bhi apne 52-week high ke aas paas hai. Analysts mostly 'Moderate Buy' keh rahe hain aur target ₹2,400-₹2,700 tak ka de rahe hain. Par kuch log 'Sell' rating bhi de rahe hain, so zara sambhal kar!
US mein generic drugs par prices ko lekar pressure hamesha rehta hai, khaas kar diabetes jaise common bimariyon ke liye. Jab tak Lupin market share nahi pakadta, profits kam rehne ki full possibility hai. Aur jab Xigduo XR generics ka market $514 million ka hai, toh itne players mein distribute hone par fayda kam hoga.
Lekin Lupin ki strategy badi hai. Woh FY26 mein 15+ naye products launch karne wale hain aur 2028 tak 20 complex products lane ka target hai. Agar yeh sab successful raha toh US revenue $1 billion cross kar sakta hai. Overall generic market bhi 3.8% CAGR se grow hone wala hai. Toh, competition tough hai, par Lupin ki aage ki planning solid lag rahi hai.